Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]

Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research 2019, Vol.8, p.234
Main Authors: Sekar, Krithiga, Pack, Alison
Format: Article
Language:English
Subjects:
Animal models
Cannabinoids
Cannabis
Cell adhesion & migration
Clinical trials
Convulsions & seizures
Drug dosages
Epilepsy
FDA approval
Marijuana
Nervous system
Patients
Review
Seizures
Side effects
Studies
Thyroid gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3
cites cdi_FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3
container_end_page
container_issue
container_start_page 234
container_title F1000 research
container_volume 8
creator Sekar, Krithiga
Pack, Alison
description Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-enriched cannabis, a plant based product without psychoactive properties which has been shown to decrease seizure frequency in animal models. More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administration's placement of Epidiolex into schedule V of the Controlled Substances Act (CSA). In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects.
doi_str_mv 10.12688/f1000research.16515.1
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_91e8e6c8296347738f83708bd446427a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_91e8e6c8296347738f83708bd446427a</doaj_id><sourcerecordid>2200705656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIRKvSV6gssWGT4L-xPUFCQlWBSpXYwAohy_FcN44m48H2TJuX4Vlxk1AaFqz8c8_55Ht9quqC4DmhQqm3jmCMIyQw0a7mRNSknpNn1SnFXMwIx_T5k_1JdZ7Suhhw0zBB5cvqhGFVc9Lg0-rX1eBbHzq4RyYh067H3maUVxDNsEUuRJQjmLyBPqPgUAQXjc0hbhEMvoMhbRfIIBs2Q4QV9MlPUESThzt05_Oq1FywY0KhL_AJYgIEzoHNCX1_OPpSIO_QABAPvgViyAxDDBO0P15VL5zpEpwf1rPq28err5efZzdfPl1ffriZWS45mUlcu1Y54MCEkYLLJa2ZhLpuBObOUYypEcTW3OFa1IIz17ZKcMusUY0iLTurrvfcNpi1HqLfmLjVwXi9uwjxVpuYve1ANwQUCKtoIxiXkimnmMRq2XIuOJWmsN7vWcO43EBry-ii6Y6gx5Xer_RtmLRgjSisAnhzAMTwc4SU9cYnC11neghj0rT8HKGUSlWkr_-RrsMY-zIqTUvXctduUYm9ysaQUvnDx8cQrHeJ0keJ0rtEaVKMF09bebT9yU8RLPYCZ-zY5e0DRf_F_J_-G31s3S4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2200705656</pqid></control><display><type>article</type><title>Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Sekar, Krithiga ; Pack, Alison</creator><creatorcontrib>Sekar, Krithiga ; Pack, Alison</creatorcontrib><description>Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-enriched cannabis, a plant based product without psychoactive properties which has been shown to decrease seizure frequency in animal models. More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administration's placement of Epidiolex into schedule V of the Controlled Substances Act (CSA). In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects.</description><identifier>ISSN: 2046-1402</identifier><identifier>EISSN: 2046-1402</identifier><identifier>DOI: 10.12688/f1000research.16515.1</identifier><identifier>PMID: 30854190</identifier><language>eng</language><publisher>England: Faculty of 1000 Ltd</publisher><subject>Animal models ; Cannabinoids ; Cannabis ; Cell adhesion &amp; migration ; Clinical trials ; Convulsions &amp; seizures ; Drug dosages ; Epilepsy ; FDA approval ; Marijuana ; Nervous system ; Patients ; Review ; Seizures ; Side effects ; Studies ; Thyroid gland</subject><ispartof>F1000 research, 2019, Vol.8, p.234</ispartof><rights>Copyright: © 2019 Sekar K and Pack A</rights><rights>Copyright: © 2019 Sekar K and Pack A. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2019 Sekar K and Pack A 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3</citedby><cites>FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3</cites><orcidid>0000-0002-7941-7866</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2200705656/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2200705656?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,25732,27902,27903,27904,36991,36992,44569,53770,53772,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30854190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sekar, Krithiga</creatorcontrib><creatorcontrib>Pack, Alison</creatorcontrib><title>Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]</title><title>F1000 research</title><addtitle>F1000Res</addtitle><description>Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-enriched cannabis, a plant based product without psychoactive properties which has been shown to decrease seizure frequency in animal models. More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administration's placement of Epidiolex into schedule V of the Controlled Substances Act (CSA). In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects.</description><subject>Animal models</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>Cell adhesion &amp; migration</subject><subject>Clinical trials</subject><subject>Convulsions &amp; seizures</subject><subject>Drug dosages</subject><subject>Epilepsy</subject><subject>FDA approval</subject><subject>Marijuana</subject><subject>Nervous system</subject><subject>Patients</subject><subject>Review</subject><subject>Seizures</subject><subject>Side effects</subject><subject>Studies</subject><subject>Thyroid gland</subject><issn>2046-1402</issn><issn>2046-1402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1uEzEUhUcIRKvSV6gssWGT4L-xPUFCQlWBSpXYwAohy_FcN44m48H2TJuX4Vlxk1AaFqz8c8_55Ht9quqC4DmhQqm3jmCMIyQw0a7mRNSknpNn1SnFXMwIx_T5k_1JdZ7Suhhw0zBB5cvqhGFVc9Lg0-rX1eBbHzq4RyYh067H3maUVxDNsEUuRJQjmLyBPqPgUAQXjc0hbhEMvoMhbRfIIBs2Q4QV9MlPUESThzt05_Oq1FywY0KhL_AJYgIEzoHNCX1_OPpSIO_QABAPvgViyAxDDBO0P15VL5zpEpwf1rPq28err5efZzdfPl1ffriZWS45mUlcu1Y54MCEkYLLJa2ZhLpuBObOUYypEcTW3OFa1IIz17ZKcMusUY0iLTurrvfcNpi1HqLfmLjVwXi9uwjxVpuYve1ANwQUCKtoIxiXkimnmMRq2XIuOJWmsN7vWcO43EBry-ii6Y6gx5Xer_RtmLRgjSisAnhzAMTwc4SU9cYnC11neghj0rT8HKGUSlWkr_-RrsMY-zIqTUvXctduUYm9ysaQUvnDx8cQrHeJ0keJ0rtEaVKMF09bebT9yU8RLPYCZ-zY5e0DRf_F_J_-G31s3S4</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Sekar, Krithiga</creator><creator>Pack, Alison</creator><general>Faculty of 1000 Ltd</general><general>F1000 Research Limited</general><general>F1000 Research Ltd</general><scope>C-E</scope><scope>CH4</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7941-7866</orcidid></search><sort><creationdate>2019</creationdate><title>Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]</title><author>Sekar, Krithiga ; Pack, Alison</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animal models</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>Cell adhesion &amp; migration</topic><topic>Clinical trials</topic><topic>Convulsions &amp; seizures</topic><topic>Drug dosages</topic><topic>Epilepsy</topic><topic>FDA approval</topic><topic>Marijuana</topic><topic>Nervous system</topic><topic>Patients</topic><topic>Review</topic><topic>Seizures</topic><topic>Side effects</topic><topic>Studies</topic><topic>Thyroid gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sekar, Krithiga</creatorcontrib><creatorcontrib>Pack, Alison</creatorcontrib><collection>F1000Research</collection><collection>Faculty of 1000</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>F1000 research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sekar, Krithiga</au><au>Pack, Alison</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]</atitle><jtitle>F1000 research</jtitle><addtitle>F1000Res</addtitle><date>2019</date><risdate>2019</risdate><volume>8</volume><spage>234</spage><pages>234-</pages><issn>2046-1402</issn><eissn>2046-1402</eissn><abstract>Medically refractory epilepsy remains an area of intense clinical and scientific interest since a significant porportion of patients continue to suffer from debilitating seizures despite available therapies. In this setting, recent studies have focused on assessing the benefits of cannabidiol (CBD)-enriched cannabis, a plant based product without psychoactive properties which has been shown to decrease seizure frequency in animal models. More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administration's placement of Epidiolex into schedule V of the Controlled Substances Act (CSA). In this review, we summarize the major findings of several recent large-scale studies using this product with a focus on its adverse effects.</abstract><cop>England</cop><pub>Faculty of 1000 Ltd</pub><pmid>30854190</pmid><doi>10.12688/f1000research.16515.1</doi><orcidid>https://orcid.org/0000-0002-7941-7866</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2046-1402
ispartof F1000 research, 2019, Vol.8, p.234
issn 2046-1402
2046-1402
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_91e8e6c8296347738f83708bd446427a
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Animal models
Cannabinoids
Cannabis
Cell adhesion & migration
Clinical trials
Convulsions & seizures
Drug dosages
Epilepsy
FDA approval
Marijuana
Nervous system
Patients
Review
Seizures
Side effects
Studies
Thyroid gland
title Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects [version 1; peer review: 3 approved]
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A58%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epidiolex%20as%20adjunct%20therapy%20for%20treatment%20of%20refractory%20epilepsy:%20a%20comprehensive%20review%20with%20a%20focus%20on%20adverse%20effects%20%5Bversion%201;%20peer%20review:%203%20approved%5D&rft.jtitle=F1000%20research&rft.au=Sekar,%20Krithiga&rft.date=2019&rft.volume=8&rft.spage=234&rft.pages=234-&rft.issn=2046-1402&rft.eissn=2046-1402&rft_id=info:doi/10.12688/f1000research.16515.1&rft_dat=%3Cproquest_doaj_%3E2200705656%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4741-705fd8fe4e36a7647b2537e559604ff2002a61c54f0565643fdd864c3ca8981d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2200705656&rft_id=info:pmid/30854190&rfr_iscdi=true